Standout Papers

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinic... 2021 2026 2022 2024331
  1. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology
  2. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment (2024)
    Antonio Passaro, Maise Al Bakir et al. Cell
  3. Overcoming therapy resistance in EGFR-mutant lung cancer (2021)
    Antonio Passaro, Pasi A. Jänne et al. Nature Cancer
  4. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies (2022)
    Antonio Passaro, Julie R. Brahmer et al. Journal of Clinical Oncology
  5. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology

Citation Impact

1 from Science/Nature 53 standout
Sub-graph 1 of 24

Citing Papers

An Antioxidative and Active Shrinkage Hydrogel Integratedly Promotes Re‐Epithelization and Skin Constriction for Enhancing Wound Closure
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
2 intermediate papers

Works of Antonio Passaro being referenced

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Standout
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
2017

Author Peers

Author PRM Oncology Molecular Biology Last Decade Papers Cites
Antonio Passaro 2035 1942 927 116 3.1k
Annikka Linnala‐Kankkunen 74 34 283 22 525
Naras M. Lapsys 4 17 228 11 336
Heather Dryburgh 5 239
LW Burgess 31 30 586
Paul E. Bigeleisen 52 2 35 1.1k

All Works

Loading papers...

Rankless by CCL
2026